CGRP mAb Iv denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for cgrp mab iv are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Your IV CGRP Monoclonal Antibody — Duplicate Therapy

Humana's "duplicate therapy" denial means the plan has identified another drug in your current regimen that it considers to serve the same therapeutic purpose as the intravenous CGRP monoclonal antibody (such as erenumab, fremanezumab, galcanezumab, or eptinezumab) prescribed for migraine prevention. This denial frequently arises when a patient is transitioning between CGRP agents, is trying a second CGRP mAb after inadequate response to a first, or when plan records are not yet updated to reflect that a prior agent was discontinued. It is highly appealable because switching within a drug class is clinically standard and distinct from true duplication.

## Why This Denial Is Appealable

The clinical rationale for prescribing a second CGRP monoclonal antibody is well-recognized: patients who do not respond adequately to one agent in the class may respond to another due to differences in mechanism of action, target epitope, or dosing schedule. True duplicate therapy implies concurrent use with no clinical distinction — your prescriber can document why these are not therapeutically equivalent in your case, or confirm that the prior agent was discontinued.

## Federal Appeal Framework

• Internal appeal: Submit under ACA §2719 / ERISA §503 within the deadline on your denial letter.
• External review: If Humana upholds the denial, escalate to an independent external review organization within approximately four months of the final internal denial.
• Expedited review: Request if you are experiencing a debilitating migraine frequency that makes delay a significant health risk.

## Documentation to Gather

1. Discontinuation records — if a prior CGRP agent was discontinued, include the chart note or pharmacy record confirming discontinuation date and reason. 2. Inadequate-response documentation — chart notes showing the dates, duration, and outcome of any prior CGRP agent trial, including documented lack of efficacy or tolerability issues. 3. Prescriber letter — explains the clinical distinction between the prior agent and the newly prescribed one, and why the switch is medically necessary rather than duplicative. 4. Humana coverage policy — obtain Humana's published criteria for CGRP mAb coverage and duplicate-therapy definitions; confirm whether switching within class is explicitly addressed. 5. Current medication list — a current, dated medication list from the prescriber confirming no concurrent CGRP agent is active.

## Criteria-Mapping Structure

| Duplicate-Therapy Criterion (per Humana policy) | Evidence Demonstrating Non-Duplication | |---|---| | Prior agent discontinued | [Pharmacy record or chart note, date] | | Clinical rationale for class switch | [Prescriber letter, inadequate-response notes, dates] | | No concurrent CGRP agent in regimen | [Current medication list, date] |